CC
GBIO

Casdin Capital’s Generation Bio GBIO Stock Holding History

Casdin Capital’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-132,428
Closed -$9.72M – 45
2022
Q1 		$9.72M Hold
132,428
– – 0.44% 35
2021
Q4 		$9.38M Hold
132,428
– – 0.26% 46
2021
Q3 		$33.2M Sell
132,428
-28,693
-18% -$6.87M 0.83% 32
2021
Q2 		$43.3M Hold
161,121
– – 1.1% 26
2021
Q1 		$45.9M Hold
161,121
– – 1.37% 20
2020
Q4 		$45.7M Hold
161,121
– – 1.36% 17
2020
Q3 		$49.8M Hold
161,121
– – 2.23% 12
2020
Q2 		$33.8M Buy
+161,121
New +$35.9M 2% 17

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return